Localized immune tolerance from FasL-functionalized PLG scaffolds.

[1]  S. Dalton,et al.  Human beige adipocytes for drug discovery and cell therapy in metabolic diseases , 2020, Nature Communications.

[2]  E. Yolcu,et al.  Pancreatic islets engineered with a FasL protein induce systemic tolerance at the induction phase that evolves into long‐term graft‐localized immune privilege , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  Andrés J. García,et al.  Evaluation of encapsulating and microporous nondegradable hydrogel scaffold designs on islet engraftment in rodent models of diabetes , 2018, Biotechnology and bioengineering.

[4]  Christopher T. Johnson,et al.  Local immunomodulation with Fas ligand-engineered biomaterials achieves allogeneic islet graft acceptance , 2018, Nature Materials.

[5]  L. Shea,et al.  Evaluation of biomaterial scaffold delivery of IL-33 as a localized immunomodulatory agent to support cell transplantation in adipose tissue. , 2018, Journal of immunology and regenerative medicine.

[6]  Ryan M. Pearson,et al.  Conjugation of Transforming Growth Factor Beta to Antigen-Loaded Poly(lactide- co-glycolide) Nanoparticles Enhances Efficiency of Antigen-Specific Tolerance. , 2017, Bioconjugate chemistry.

[7]  Ryan M. Pearson,et al.  Controlled Delivery of Single or Multiple Antigens in Tolerogenic Nanoparticles Using Peptide-Polymer Bioconjugates. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  Ryan M. Pearson,et al.  In vivo reprogramming of immune cells: Technologies for induction of antigen‐specific tolerance , 2017, Advanced drug delivery reviews.

[9]  S. Ostad,et al.  Biotin decorated PLGA nanoparticles containing SN-38 designed for cancer therapy , 2017, Artificial cells, nanomedicine, and biotechnology.

[10]  Ryan M. Pearson,et al.  Tuning the Selectivity of Dendron Micelles Through Variations of the Poly(ethylene glycol) Corona. , 2016, ACS nano.

[11]  K. Chaloner,et al.  Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia , 2016, Diabetes Care.

[12]  R. Gower,et al.  Transforming growth factor-beta 1 delivery from microporous scaffolds decreases inflammation post-implant and enhances function of transplanted islets. , 2016, Biomaterials.

[13]  P. Couvreur,et al.  Peptide conjugation: before or after nanoparticle formation? , 2014, Bioconjugate chemistry.

[14]  W. Lowe,et al.  Enhancing Human Islet Transplantation by Localized Release of Trophic Factors From PLG Scaffolds , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  S. Miller,et al.  Quantification of particle-conjugated or particle-encapsulated peptides on interfering reagent backgrounds. , 2014, BioTechniques.

[16]  Shutao Zhao,et al.  Testicular defense systems: immune privilege and innate immunity , 2014, Cellular and Molecular Immunology.

[17]  G. Coukos,et al.  Tumor Endothelium FasL Establishes a Selective Immune Barrier Promoting Tolerance in Tumors , 2014, Nature Medicine.

[18]  S. Miller,et al.  A Biodegradable Nanoparticle Platform for the Induction of Antigen-Specific Immune Tolerance for Treatment of Autoimmune Disease , 2014, ACS nano.

[19]  M. Atkinson,et al.  Type 1 diabetes , 2014, The Lancet.

[20]  I. Yaniv,et al.  Immunomodulation with donor regulatory T cells armed with Fas-ligand alleviates graft-versus-host disease. , 2013, Experimental hematology.

[21]  E. Yolcu,et al.  Killer Treg cells ameliorate inflammatory insulitis in non-obese diabetic mice through local and systemic immunomodulation. , 2013, International immunology.

[22]  E. Yolcu,et al.  Immunomodulation with SA-FasL protein as an effective means of preventing islet allograft rejection in chemically diabetic NOD mice. , 2013, Transplantation proceedings.

[23]  W. Lowe,et al.  Porous Scaffolds Support Extrahepatic Human Islet Transplantation, Engraftment, and Function in Mice , 2013, Cell transplantation.

[24]  E. Yolcu,et al.  Immunomodulation with regulatory T cells and Fas-ligand ameliorate established inflammatory colitis , 2013, Gut.

[25]  N. Comolli,et al.  An integrated experimental and modeling approach to propose biotinylated PLGA microparticles as versatile targeting vehicles for drug delivery , 2013, Progress in Biomaterials.

[26]  M. Schwartz,et al.  The privileged immunity of immune privileged organs: the case of the eye , 2012, Front. Immun..

[27]  B. Hering,et al.  Potent Induction Immunotherapy Promotes Long‐Term Insulin Independence After Islet Transplantation in Type 1 Diabetes , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[28]  B. Hering,et al.  Extrahepatic islet transplantation with microporous polymer scaffolds in syngeneic mouse and allogeneic porcine models. , 2011, Biomaterials.

[29]  C. Lacelle,et al.  Pancreatic Islets Engineered with SA-FasL Protein Establish Robust Localized Tolerance by Inducing Regulatory T Cells in Mice , 2011, The Journal of Immunology.

[30]  I. Yaniv,et al.  Killer Treg restore immune homeostasis and suppress autoimmune diabetes in prediabetic NOD mice. , 2011, Journal of autoimmunity.

[31]  L. Piemonti,et al.  Alternative Transplantation Sites for Pancreatic Islet Grafts , 2011, Current diabetes reports.

[32]  G. Warnock,et al.  Reduced Progression of Diabetic Microvascular Complications With Islet Cell Transplantation Compared With Intensive Medical Therapy , 2011, Transplantation.

[33]  R. Fairchild,et al.  CD4+CD25+ regulatory T cells utilize FasL as a mechanism to restrict DC priming functions in cutaneous immune responses , 2010, European journal of immunology.

[34]  K. Anseth,et al.  Inducing local T cell apoptosis with anti-Fas-functionalized polymeric coatings fabricated via surface-initiated photopolymerizations. , 2010, Biomaterials.

[35]  T. Whiteside,et al.  Human Circulating CD4+CD25highFoxp3+ Regulatory T Cells Kill Autologous CD8+ but Not CD4+ Responder Cells by Fas-Mediated Apoptosis1 , 2009, The Journal of Immunology.

[36]  Y. Sagiv,et al.  Apoptosis as a mechanism of T‐regulatory cell homeostasis and suppression , 2008, Immunology and cell biology.

[37]  J. Ijzermans,et al.  The Choice of Anatomical Site for Islet Transplantation , 2008, Cell transplantation.

[38]  C. Lacelle,et al.  Induction of Tolerance to Cardiac Allografts Using Donor Splenocytes Engineered to Display on Their Surface an Exogenous Fas Ligand Protein1 , 2008, The Journal of Immunology.

[39]  Christopher B. Rives,et al.  Extracellular Matrix Protein-Coated Scaffolds Promote the Reversal of Diabetes After Extrahepatic Islet Transplantation , 2008, Transplantation.

[40]  Zhiliang Wang,et al.  Rapamycin-conditioned, alloantigen-pulsed dendritic cells promote indefinite survival of vascularized skin allografts in association with T regulatory cell expansion. , 2008, Transplant immunology.

[41]  R. Gill,et al.  Islet Allograft Rejection by Contact‐Dependent CD8+ T cells: Perforin and FasL Play Alternate but Obligatory Roles 1 , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[42]  D. Kaufman,et al.  The epididymal fat pad as a transplant site for minimal islet mass. , 2007, Transplantation.

[43]  E. Yolcu,et al.  A novel multimeric form of FasL modulates the ability of diabetogenic T cells to mediate type 1 diabetes in an adoptive transfer model. , 2007, Molecular immunology.

[44]  M. Rickels,et al.  Glycemic thresholds for activation of counterregulatory hormone and symptom responses in islet transplant recipients. , 2007, The Journal of clinical endocrinology and metabolism.

[45]  B. Melchior,et al.  CNS immune privilege: hiding in plain sight , 2006, Immunological reviews.

[46]  Philippe Morel,et al.  International trial of the Edmonton protocol for islet transplantation. , 2006, The New England journal of medicine.

[47]  Christopher B. Rives,et al.  Polymer Scaffolds as Synthetic Microenvironments for Extrahepatic Islet Transplantation , 2006, Transplantation.

[48]  S. Ziegler,et al.  Adaptive Islet-Specific Regulatory CD4 T Cells Control Autoimmune Diabetes and Mediate the Disappearance of Pathogenic Th1 Cells In Vivo1 , 2006, The Journal of Immunology.

[49]  M. Battaglia,et al.  Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. , 2005, Blood.

[50]  C. Berne,et al.  Current status of clinical islet transplantation. , 2005, Transplantation.

[51]  A. Shapiro,et al.  The Portal Immunosuppressive Storm: Relevance to Islet Transplantation? , 2005, Therapeutic drug monitoring.

[52]  D. Green,et al.  Regulation of Activation-induced Fas (CD95/Apo-1) Ligand Expression in T Cells by the Cyclin B1/Cdk1 Complex* , 2004, Journal of Biological Chemistry.

[53]  A. Grandien,et al.  CD4+ T cells kill Id+ B-lymphoma cells: FasLigand-Fas interaction is dominant in vitro but is redundant in vivo , 2004, Cancer Immunology, Immunotherapy.

[54]  H. Auchincloss,et al.  Allorecognition and effector pathways of islet allograft rejection in normal versus nonobese diabetic mice. , 2003, Journal of the American Society of Nephrology : JASN.

[55]  Narendra P. Singh,et al.  Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. , 2002, Immunity.

[56]  H. Auchincloss,et al.  The role of autoimmunity in islet allograft destruction: major histocompatibility complex class II matching is necessary for autoimmune destruction of allogeneic islet transplants after T-cell costimulatory blockade. , 2002, Diabetes.

[57]  M. Papiernik,et al.  Modulation of Fas-Dependent Apoptosis: A Dynamic Process Controlling Both the Persistence and Death of CD4 Regulatory T Cells and Effector T Cells1 , 2002, The Journal of Immunology.

[58]  P. Fink,et al.  Fas Ligand Costimulates the In Vivo Proliferation of CD8+ T Cells1 , 2000, The Journal of Immunology.

[59]  Andrew S. Diamond,et al.  An Essential Contribution by IFN-γ to CD8+ T Cell-Mediated Rejection of Pancreatic Islet Allografts1 , 2000, The Journal of Immunology.

[60]  Myung-Shik Lee,et al.  Inhibition of Autoimmune Diabetes by Fas Ligand: The Paradox Is Solved1 , 2000, The Journal of Immunology.

[61]  G. Elgue,et al.  Damage to porcine islets of Langerhans after exposure to human blood in vitro, or after intraportal transplantation to cynomologus monkeys: protective effects of sCR1 and heparin. , 2000, Transplantation.

[62]  J. Corbett,et al.  Evidence that beta cell death in the nonobese diabetic mouse is Fas independent. , 1999, Journal of immunology.

[63]  David J. Mooney,et al.  DNA delivery from polymer matrices for tissue engineering , 1999, Nature Biotechnology.

[64]  R. Schwartz,et al.  Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. , 1999, Journal of immunology.

[65]  Y. Kim,et al.  Apoptosis of pancreatic β‐cells detected in accelerated diabetes of NOD mice: no role of Fas‐Fas ligand interaction in autoimmune diabetes , 1999, European journal of immunology.

[66]  G. Stassi,et al.  Nitric Oxide Primes Pancreatic β Cells for Fas-mediated Destruction in Insulin-dependent Diabetes Mellitus , 1997, The Journal of experimental medicine.

[67]  Y. Matsuzawa,et al.  Requirement of Fas for the Development of Autoimmune Diabetes in Nonobese Diabetic Mice , 1997, The Journal of experimental medicine.

[68]  D. Hanahan,et al.  Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction , 1997, Nature Medicine.

[69]  D. Vaux,et al.  Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[70]  O. Korsgren.  Acute cellular xenograft rejection , 1997 .

[71]  R Langer,et al.  Novel approach to fabricate porous sponges of poly(D,L-lactic-co-glycolic acid) without the use of organic solvents. , 1996, Biomaterials.

[72]  D. Green,et al.  Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege , 1995, Science.

[73]  D. Bellgrau,et al.  A role for CD95 ligand in preventing graft rejection , 1995, Nature.

[74]  S. Ju,et al.  Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation , 1995, Nature.

[75]  C. Smith,et al.  Fas ligand mediates activation-induced cell death in human T lymphocytes , 1995, The Journal of experimental medicine.

[76]  J. Mountz,et al.  Correction of accelerated autoimmune disease by early replacement of the mutated lpr gene with the normal Fas apoptosis gene in the T cells of transgenic MRL-lpr/lpr mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[77]  F. Ramsdell,et al.  Fas transduces activation signals in normal human T lymphocytes , 1993, The Journal of experimental medicine.

[78]  A. Singer,et al.  Characterization of primary T cell subsets mediating rejection of pancreatic islet grafts. , 1989, Journal of immunology.

[79]  R. Rajotte,et al.  Beta-cell destruction in NOD mice correlates with Fas (CD95) expression on beta-cells and proinflammatory cytokine expression in islets. , 1999, Diabetes.

[80]  J. Chung,et al.  Fas is expressed in murine pancreatic islet cells and an insulinoma cell line but does not mediate their apoptosis in vitro. , 1999, Autoimmunity.